1 January 2022 in Cancer Management and Research
Objective: To develop an approach for automatically analyzing bone metastases (BMs) on bone scintigrams based on deep learning technology. Methods: This research included a bone scan classification model, a regional segmentation model, an assessment model for tumor burden and a diagnostic report generation model. Two hundred eighty patients with BMs and 341 patients with non-BMs were involved. Eighty percent of cases were randomly extracted from two groups as training set. Remaining cases were as testing set. A deep residual convolutional neural network with different structures was used to determine whether metastatic bone lesions existed, regions of lesions were automatically segmented. Bone scan tumor burden index (BSTBI) was calculated; finally, diagnostic report could be automatically generated. The sensitivity, specificity and accuracy of classification model were compared with three physicians with different clinical experience. The Dice coefficient evaluated the effect of segmentation model and compared to the result of nnU-Net model. The correlation between BSTBI and blood alkaline phosphatase (ALP) level was analyzed to verify the efficiency of BSTBI. The performance of report generation model was evaluated by the accuracy of interpretation of report. Results: In testing set, the sensitivity, specificity and accuracy of classification model were 92.59%, 85.51% and 88.62%, respectively. The accuracy showed no statistical difference with moderately and experienced physicians and obviously outperformed the inexperienced. The Dice coefficient of BMs area was 0.7387 in segmentation stage. Based on the whole model frame, our segmentation model outperformed the nnU-Net. BSTBI value changed as the BMs changed. There was a positive correlation between BSTBI and ALP level. The accuracy of report generation model was 78.05%. Conclusion: Deep learning based on automatic analysis frameworks for BMs can accurately identify BMs, preliminarily realize a fully automatic analysis process from raw data to report generation. BSTBI can be used as a quantitative evaluation indicator to assess the effect of therapy on BMs in different patients or in the same patient before and after treatment.
19 May 2026 in Molecular Cancer Therapeutics
PTC596 has been studied in advanced solid tumors in clinical trials. However, the effects of PTC596 alone or in combination with programmed cell death protein 1 (PD-1) blockade in hepatocellular carcinoma (HCC) remain unclear. Subcutaneous tumor models in both Balb/c and C57BL/6 mice were used to evaluate the effects of PTC596 alone or combined with an anti–PD-1 antibody (anti–PD-1) on tumor growth control, survival, and tumor-infiltrating immune cells. The underlying mechanism was investigated by immunofluorescence, flow cytometry, RNA sequencing (RNA-seq), and IHC. We found that PTC596 not only killed HCC cells in vitro but also controlled H22 and Hepa1-6 tumor growth in vivo. PTC596 promoted the infiltration of CD8+ T cells in H22 and Hepa1-6 models. Importantly, combination therapy (PTC596 plus anti–PD-1) showed superior antitumor efficacy and prolonged mouse survival. Moreover, combination therapy induced robust antitumor immune activity by activating mature dendritic cells, CD8+ T cells, natural killer cells, inflammatory monocytes, and total macrophages while suppressing the infiltration of B cells and M2-type macrophages. RNA-seq confirmed that the antitumor effects of PTC596 alone or in combination with anti–PD-1 relied on the regulation of inflammation- and immune-associated pathways. Furthermore, combination therapy induced long-term immunologic memory in “cured” mice, as these mice were unaffected by tumor rechallenge after the original tumors were eliminated. Therefore, PTC596 is not only an effective antitumor drug for HCC but also supports the formation of a favorable tumor microenvironment that enhances the effect of PD-1 blockade. This study supports that PTC596 combined with PD-1 blockade could be a promising strategy for HCC.